View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 7, 2021

Vaxart starts subject enrolment in trial of oral vaccine for Covid-19

Approximately 96 subjects in the US will be given the vaccine as part of the trial this month. 

Vaxart has commenced participant recruitment in the Phase II clinical trial of S-only oral tablet vaccine candidate for Covid-19.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

This month, the company expects to start dosing the first of 96 US volunteers categorised equally between Covid 19 naïve and messenger ribonucleic acid (mRNA) vaccinated participants.

The Phase II Covid-19 programme will also be conducted outside of the US. In the initial stage, a trial is expected to be launched in India later this year.

Vaxart founder and chief scientific officer Dr Sean Tucker said: “We’re very excited to start Phase II trials of our S-only vaccine candidate because in our nonhuman primate studies, our S-only vaccine produced much higher serum antibody levels than the S+N construct did.

“Vaxart’s new trials will generate key data that will allow us to compare the S-only and S+N vaccine candidates and help us decide on the best development path forward for our Covid 19 vaccine programme, particularly in the face of emerging variant strains.”

The company’s vaccines are created to be used as tablets that require no refrigeration for storage and shipping.

Vaxart CEO Andrei Floroiu said: “An oral vaccine has the potential to dramatically impact the world’s response to the Covid 19 pandemic and to improve global public health.

“It can be easier and faster to administer than injectables and can help mitigate vaccine hesitancy, as many of those unwilling to get vaccinated by needle would take an oral tablet vaccine.”

Vaxart’s tablet vaccine delivery platform can potentially offer recombinant vaccines, aiding the company to create oral formulations of presently sold vaccines and to develop recombinant vaccines for novel indications.

At present, the development programmes of the company comprise tablet vaccines to offer protection against coronavirus, seasonal influenza, norovirus and respiratory syncytial virus (RSV).

Vaxart is also developing a therapeutic human papillomavirus (HPV) vaccine.

In September last year, Vaxart received clearance from the US Food and Drug Administration to conduct a Phase I trial of its Covid 19 vaccine candidate.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU